Post by
SPCEO1 on Jan 04, 2022 5:28pm
Sales and Options Update
I think I am going to put the Grumpy Grader into hibernation for now and hope that good phase 1a results and a new IR person can get the ship headed in the right direction.
I normally would update sales and options outstanding in the Weekly Report Card, so instead I will highlight them whenever it seems noteworthy. Trogarzo sales in December had a couple of good weeks but I am unsure if this reflects European sales or better US sales. Egrifta sales, which we would like to be doing better since those carry twice the profit margin of Trogarzo sales were OK but nothing noteworthy through most od December (the full month's results are not available yet but the week between Christmas and New Years is often slow). After the next earnings report we may be able to determine what impact, if any, there might be in the Bloomberg sales estimator for European Trogarzo sales.
The number of call options on THTX continues to expand, which indicates a degree of bullishness but the overall option total remains quite small as THTX is just not on many people's radar screens despite the proximity to what could be company defining results from the phase 1a cancer trial. There are just a little shy of 3,000 open call options at this time and just 29 open put positions. Someone added a bunch of January calls clearly hoping for a data release or some significant info before options expiration in the middle of the month.
Comment by
PWIB123 on Jan 05, 2022 9:53am
Your critique of the company has been dead on, and I appreciate the extensive efforts you've taken to keep us informed. My timeline is ticking, but I'm still super hopeful for what might transpire within the next 26 days.